Navigation Links
Progen Technology Switches on Cancer Fighting Genes and Inhibits Tumor Growth
Date:4/20/2009

nt and commercialization of small molecule pharmaceuticals primarily for the treatment of cancer. Progen has built a focus and strength in anti-cancer drug discovery and development. Progen targets the multiple mechanisms of cancer across its three technology platforms of angiogenesis, epigenetics and cell proliferation. Progen has operations in Australia and the United States of America. www.progen-pharma.com

    For more information:
    Dr Laurence Marton
    Chief Scientific Officer
    Phone: 650-906-5893

This release contains forward-looking statements that are based on current management expectations. These statements may differ materially from actual future events or results due to certain risks and uncertainties, including without limitation, risks associated with drug development and manufacture, risks inherent in the extensive regulatory approval process mandated by, amongst others, the United States Food and Drug Administration and the Australian Therapeutic Goods Administration, delays in obtaining the necessary approvals for clinical testing, patient recruitment, delays in the conduct of clinical trials, market acceptance of PI-88, PG11047, PG545, PG562, PG11122, PG11144 and other drugs, future capital needs, general economic conditions, and other risks and uncertainties detailed from time to time in the Company's filings with the Australian Securities Exchange and the United States Securities and Exchange Commission. Moreover, there can be no assurance that others will not independently develop similar products or processes or design around patents owned or licensed by the Company, or that patents owned or licensed by the Company will provide meaningful protection or competitive advantages.

Abstract Details

Abstract Number: LB-173

Presentation Title: Novel oligoamine/polyamine analogues inhibit l
'/>"/>

SOURCE Progen Pharmaceuticals Limited
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. ProGenTech Targets Clinical Diagnostics and Applied Sciences Markets with Human Genetic Signatures Deal
2. ProGenTech Limited Appoints Executive Management Team
3. ProGenTech Completes $21 Million Series C Financing
4. Radioactive progenies of thoron can be measured accurately, thanks to the PTB
5. Neural progenitor cells as reservoirs for HIV in the brain
6. Progen Investor Teleconference Dial In Details
7. Elusive pancreatic progenitor cells found in mice
8. Imaging neural progenitor cells in the living human brain
9. Progen Update on Phase 3 Clinical Program for PI-88 in Liver Cancer
10. Progen to Present Additional Analysis of Data from PI-88 Phase 2 Liver Cancer Study at American Association for the Study of Liver Diseases
11. Yashoda Cancer Institute Treats First Patient in India Using RapidArc Radiotherapy Technology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2014)... York (PRWEB) September 22, 2014 ... the use of power morcellators ( http://www.gynecaremorcellatorlawsuit.com/ ) ... a new report detailing the continued use of ... federal regulators that specifically discouraged these procedures. According ... that the potential cancer risks associated with power ...
(Date:9/22/2014)... Gray HealthDay Reporter MONDAY, ... woman wonders: What can I do to help ensure a ... as prescribed may play a role in reducing the risk ... The researchers found that mothers of children with autism were ... during pregnancy than those whose children seem to be developing ...
(Date:9/22/2014)... In a continued effort to support ... is launching an awareness campaign inspired by the ice ... aims to raise awareness and funds for the cause. ... in the air and trying to catch it while ... a nominee does not complete the challenge within 24 ...
(Date:9/22/2014)... Ind. Researchers have developed a chip capable ... use the new system to test the effectiveness ... new system, called a tumor-microenvironment-on-chip (T-MOC) device, will ... tumors and the barriers that prevent the targeted ... Purdue University associate professor of mechanical engineering., Researchers ...
(Date:9/22/2014)... 22, 2014 The New York Group ... Surgery at the Icahn School of Medicine at Mount ... Group for Plastic Surgery gives residents of New York ... team of world-renowned plastic surgeons performing innovative reconstructive and ... MD, who led NYGPS, was named the Director of ...
Breaking Medicine News(10 mins):Health News:Power Morcellator News: Bernstein Liebhard LLP Notes New Report Detailing Continued Use of Uterine Morcellation Despite FDA Warning 2Health News:Power Morcellator News: Bernstein Liebhard LLP Notes New Report Detailing Continued Use of Uterine Morcellation Despite FDA Warning 3Health News:Power Morcellator News: Bernstein Liebhard LLP Notes New Report Detailing Continued Use of Uterine Morcellation Despite FDA Warning 4Health News:Could Low Iron Intake During Pregnancy Raise Autism Risk? 2Health News:Could Low Iron Intake During Pregnancy Raise Autism Risk? 3Health News:Blind Egg Challenge Raises Awareness for Foundation Fighting Blindness 2Health News:New chip promising for tumor-targeting research 2Health News:The New York Group for Plastic Surgery Joins Mount Sinai Doctors 2Health News:The New York Group for Plastic Surgery Joins Mount Sinai Doctors 3
... 24 Sopherion Therapeutics, LLC, a biopharmaceutical company ... therapies, has announced the appointment of Dr. Marcel ... Affairs. Prior to joining Sopherion, Dr. Rozencweig was ... and a member of the Sopherion Protocol Development ...
... ON, Feb. 24 /PRNewswire-FirstCall/ - Nuvo Research Inc. (TSX: ... research and development of drug products delivered to and ... delivery technologies, today announced that Nuvo,s INSIGHT(TM) platform, developed ... fqubed, Inc., has been selected as one of four ...
... of Nearly 106 Million PrescriptionsStrong 2009 EPS Guidance ReaffirmedFourth-Quarter ... percent to $0.54 from $0.38 in 2007 , - ... from the 2003 spin-off, increased 37.2 percent to $0.59 ... volume of 26.7 million increased 9.4 percent from 2007 ...
... a medical imaging and diagnostic Company launches new Physician Billing Services ... billing services as part of its commitment to synergistically diversify the ... ... 2009 -- Bederra Corporation (Pink Sheets: BEDA), a medical ...
... 24 Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL ... and year ended December 31, 2008.(Logo: http://www.newscom.com/cgi-bin/prnh/20030226/RIGLLOGO )For ... loss of $33.4 million, or $0.91 per share, compared ... per share, in the fourth quarter of 2007. Weighted ...
... Healthcare Workers from Hazardous Drug ExposureCOLUMBUS, Ohio, Feb. 24 ... the safe handling of hazardous drugs in the healthcare ... Safe Handling Awareness Month with Monday, April 20, 2009 ... The proclamation of National Safe Handling Awareness Month ...
Cached Medicine News:Health News:Sopherion Therapeutics Announces Appointment of New Senior Executive Vice President for Clinical Affairs 2Health News:Nuvo's High Throughput Experimentation Platform Selected as 2009 Edison Award Finalist 2Health News:Nuvo's High Throughput Experimentation Platform Selected as 2009 Edison Award Finalist 3Health News:Medco Delivers Fourth-Quarter GAAP Diluted EPS Growth of 42 Percent; 2008 Full-Year GAAP Diluted EPS Growth of 31 Percent 2Health News:Medco Delivers Fourth-Quarter GAAP Diluted EPS Growth of 42 Percent; 2008 Full-Year GAAP Diluted EPS Growth of 31 Percent 3Health News:Medco Delivers Fourth-Quarter GAAP Diluted EPS Growth of 42 Percent; 2008 Full-Year GAAP Diluted EPS Growth of 31 Percent 4Health News:Medco Delivers Fourth-Quarter GAAP Diluted EPS Growth of 42 Percent; 2008 Full-Year GAAP Diluted EPS Growth of 31 Percent 5Health News:Medco Delivers Fourth-Quarter GAAP Diluted EPS Growth of 42 Percent; 2008 Full-Year GAAP Diluted EPS Growth of 31 Percent 6Health News:Medco Delivers Fourth-Quarter GAAP Diluted EPS Growth of 42 Percent; 2008 Full-Year GAAP Diluted EPS Growth of 31 Percent 7Health News:Medco Delivers Fourth-Quarter GAAP Diluted EPS Growth of 42 Percent; 2008 Full-Year GAAP Diluted EPS Growth of 31 Percent 8Health News:Medco Delivers Fourth-Quarter GAAP Diluted EPS Growth of 42 Percent; 2008 Full-Year GAAP Diluted EPS Growth of 31 Percent 9Health News:Medco Delivers Fourth-Quarter GAAP Diluted EPS Growth of 42 Percent; 2008 Full-Year GAAP Diluted EPS Growth of 31 Percent 10Health News:Medco Delivers Fourth-Quarter GAAP Diluted EPS Growth of 42 Percent; 2008 Full-Year GAAP Diluted EPS Growth of 31 Percent 11Health News:Medco Delivers Fourth-Quarter GAAP Diluted EPS Growth of 42 Percent; 2008 Full-Year GAAP Diluted EPS Growth of 31 Percent 12Health News:Medco Delivers Fourth-Quarter GAAP Diluted EPS Growth of 42 Percent; 2008 Full-Year GAAP Diluted EPS Growth of 31 Percent 13Health News:Medco Delivers Fourth-Quarter GAAP Diluted EPS Growth of 42 Percent; 2008 Full-Year GAAP Diluted EPS Growth of 31 Percent 14Health News:Medco Delivers Fourth-Quarter GAAP Diluted EPS Growth of 42 Percent; 2008 Full-Year GAAP Diluted EPS Growth of 31 Percent 15Health News:Medco Delivers Fourth-Quarter GAAP Diluted EPS Growth of 42 Percent; 2008 Full-Year GAAP Diluted EPS Growth of 31 Percent 16Health News:Medco Delivers Fourth-Quarter GAAP Diluted EPS Growth of 42 Percent; 2008 Full-Year GAAP Diluted EPS Growth of 31 Percent 17Health News:Medco Delivers Fourth-Quarter GAAP Diluted EPS Growth of 42 Percent; 2008 Full-Year GAAP Diluted EPS Growth of 31 Percent 18Health News:Medco Delivers Fourth-Quarter GAAP Diluted EPS Growth of 42 Percent; 2008 Full-Year GAAP Diluted EPS Growth of 31 Percent 19Health News:Medco Delivers Fourth-Quarter GAAP Diluted EPS Growth of 42 Percent; 2008 Full-Year GAAP Diluted EPS Growth of 31 Percent 20Health News:Medco Delivers Fourth-Quarter GAAP Diluted EPS Growth of 42 Percent; 2008 Full-Year GAAP Diluted EPS Growth of 31 Percent 21Health News:Medco Delivers Fourth-Quarter GAAP Diluted EPS Growth of 42 Percent; 2008 Full-Year GAAP Diluted EPS Growth of 31 Percent 22Health News:Medco Delivers Fourth-Quarter GAAP Diluted EPS Growth of 42 Percent; 2008 Full-Year GAAP Diluted EPS Growth of 31 Percent 23Health News:Medco Delivers Fourth-Quarter GAAP Diluted EPS Growth of 42 Percent; 2008 Full-Year GAAP Diluted EPS Growth of 31 Percent 24Health News:Medco Delivers Fourth-Quarter GAAP Diluted EPS Growth of 42 Percent; 2008 Full-Year GAAP Diluted EPS Growth of 31 Percent 25Health News:Medco Delivers Fourth-Quarter GAAP Diluted EPS Growth of 42 Percent; 2008 Full-Year GAAP Diluted EPS Growth of 31 Percent 26Health News:Medco Delivers Fourth-Quarter GAAP Diluted EPS Growth of 42 Percent; 2008 Full-Year GAAP Diluted EPS Growth of 31 Percent 27Health News:Medco Delivers Fourth-Quarter GAAP Diluted EPS Growth of 42 Percent; 2008 Full-Year GAAP Diluted EPS Growth of 31 Percent 28Health News:Medco Delivers Fourth-Quarter GAAP Diluted EPS Growth of 42 Percent; 2008 Full-Year GAAP Diluted EPS Growth of 31 Percent 29Health News:Medco Delivers Fourth-Quarter GAAP Diluted EPS Growth of 42 Percent; 2008 Full-Year GAAP Diluted EPS Growth of 31 Percent 30Health News:Bederra Corporation Launches New Billing Services Division Expected to Add up to $500,000 in Revenue 2Health News:Bederra Corporation Launches New Billing Services Division Expected to Add up to $500,000 in Revenue 3Health News:Rigel Announces Fourth Quarter and Year End 2008 Financial Results 2
(Date:9/22/2014)... DIEGO , Sept. 22, 2014  Aethlon ... targeted therapeutic devices to address infectious disease, cancer ... Defense Advanced Research Projects Agency (DARPA) has informed ... option to proceed with year four of a ... Aethlon on September 30, 2011 under DARPA,s Dialysis-Like ...
(Date:9/22/2014)... LITTLE FALLS, N.J. , Sept. 22, 2014 /PRNewswire/-- CANTEL MEDICAL ... for its fourth quarter and fiscal 2014 ended July 31, ... hold a conference call to discuss the results at 11:00 ... M. Diker , Chairman; Andrew A. Krakauer , President ... and COO; Craig A. Sheldon , Senior Vice President, ...
(Date:9/22/2014)... 22, 2014  Sutro Biopharma today announced that it ... of 2014,s Fierce 15 biotechnology companies, designating it as ... the industry.  "Sutro has earned some ... well as industry partners for what promises to be ... says John Carroll , editor of FierceBiotech ...
Breaking Medicine Technology:Aethlon Medical Receives Notice of DARPA Contract Renewal 2Aethlon Medical Receives Notice of DARPA Contract Renewal 3Aethlon Medical Receives Notice of DARPA Contract Renewal 4Cantel Medical Corp. To Hold Conference Call To Discuss Results For Its Fourth Quarter And Fiscal 2014 Ended July 31, 2014 2FierceBiotech names Sutro Biopharma as one of its "Fierce 15" Biotech Companies of 2014 2FierceBiotech names Sutro Biopharma as one of its "Fierce 15" Biotech Companies of 2014 3
... Both Shape and Volumetric Evaluation of ... Three dimensional visualization,of the right ventricle provides important ... patients with tetralogy of,Fallot (TOF), according to a paper ... 1, 107-113)., TOF is a disease that impacts ...
... April 8, 2008 ,Anesiva, Inc. (Nasdaq: ANSV ... trial evaluating Adlea(TM), its long-acting, non-opioid analgesic,drug candidate, ... In September 2007, Anesiva initiated a multicenter, ... safety and,efficacy of a single 5 or 15 ...
Cached Medicine Technology:Three Dimensional Visualization of Right Ventricle Provides Important Information for Treatment of Patients with Tetralogy of Fallot, According to a Study in The American Journal of Cardiology 2Three Dimensional Visualization of Right Ventricle Provides Important Information for Treatment of Patients with Tetralogy of Fallot, According to a Study in The American Journal of Cardiology 3Anesiva Announces Pivotal Phase 3 Clinical Trial of Adlea(TM) for Reducing Post-Surgical Pain Following Total Knee Replacement 2Anesiva Announces Pivotal Phase 3 Clinical Trial of Adlea(TM) for Reducing Post-Surgical Pain Following Total Knee Replacement 3Anesiva Announces Pivotal Phase 3 Clinical Trial of Adlea(TM) for Reducing Post-Surgical Pain Following Total Knee Replacement 4
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: